Home Featured Page 238

Featured

Latest

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved...

Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary...

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative...

Delix Therapeutics Expands Executive Leadership Team

Horizons ETFs Rebalances World’s First Psychedelics ETF

MYND Life Sciences Provides Corporate Update

Clerkenwell Signs First Multi-million Pound Contract with International Psychedelic Bio-tech Company

Real World Research in Psychedelic Science

PT252 – Joel Lambert – Ibogaine, 5-MeO-DMT, and The Warrior Tradition

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create...

1...237238239...304 Page 238 of 304

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved...

Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary...

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative...

Delix Therapeutics Expands Executive Leadership Team

Horizons ETFs Rebalances World’s First Psychedelics ETF

MYND Life Sciences Provides Corporate Update

Clerkenwell Signs First Multi-million Pound Contract with International Psychedelic Bio-tech Company

Real World Research in Psychedelic Science

PT252 – Joel Lambert – Ibogaine, 5-MeO-DMT, and The Warrior Tradition

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create...

EDITOR PICKS

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY